PD-1 and PD-L1 Inhibitors Market by Application and Geography - Forecast and Analysis 2021-2025

The PD-1 and PD-L1 inhibitors market share is expected to increase by USD 29.97 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 19.11%.

This PD-1 and PD-L1 inhibitors market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers PD-1 and PD-L1 inhibitors market segmentation by application (solid tumors and blood-related tumors) and geography (North America, Europe, Asia, and ROW). The PD-1 and PD-L1 inhibitors market report also offers information on several market vendors, including Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. among others.

What will the PD-1 and PD-L1 Inhibitors Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the PD-1 and PD-L1 Inhibitors Market Size for the Forecast Period and Other Important Statistics

"The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years."

PD-1 and PD-L1 Inhibitors Market: Key Drivers and Challenges

The reduction in cancer mortality rate is notably driving the PD-1 and PD-L1 inhibitors market growth, although factors such as the availability of alternative therapies may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the PD-1 and PD-L1 inhibitors industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key PD-1 and PD-L1 Inhibitors Market Driver

The lack of approved therapies for cancer in the past led to a high mortality rate. However, the market has witnessed a significant decrease in mortality rate owing to the increasing approvals of novel cancer therapies in recent years. While underdeveloped economies such as Niger continue to have high mortality rates, developed countries such as the US, the UK, and Canada have witnessed a significant decrease. The reduction in the mortality rate of cancer is largely due to the availability of novel drugs, including PD-1 and PD-L1 inhibitors. This proven efficacy of the cancer drugs leads to a high patient adherence ratio, thereby driving the market growth. The reducing mortality rates of cancer and the increasing adoption rates of PD-1 and PD-L1 inhibitors are encouraging vendors in the market to spend heavily on research and development (R&D) of novel drugs, which is expected to add significant value to the PD-1 and PD-L1 inhibitors market during the forecast period. 

Key PD-1 and PD-L1 Inhibitors Market Challenge

Despite the proven efficacy of PD-1 and PD-L1 inhibitors in the treatment of various types of solid tumors and blood-related tumors, the market faces a heavy threat from the presence of alternative therapies. The increasing prevalence of cancer has resulted in an urgent need for the development of more advanced therapies to treat these indications. As a result, various vendors have started developing therapies for inhibiting PARP and HER-2. These therapies are called targeted anti-cancer therapies, in which the drug works on inhibiting the growth of the cancer-causing cell in the body. There are multiple targeted therapies approved for the treatment of various types of cancer. The global pharmaceutical market has also witnessed the advent of regenerative therapies such as CAR T-cell therapy and gene therapy for the treatment of cancer. The curative nature of regenerative therapies poses a huge threat to the global PD-1 and PD-L1 inhibitors market, and the expected approval of these therapies during the forecast period is expected to increase the threat, leading to less preference for PD-1 and PD-L1 inhibitors.

This PD-1 and PD-L1 market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Market Overview

The parent market, the global pharmaceuticals market, covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. 

Who are the Major PD-1 and PD-L1 Inhibitors Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Agenus Inc.
• Amgen Inc.
• AnaptysBio Inc.
• AstraZeneca Plc
• BeiGene Ltd.
• Bristol-Myers Squibb Co.
• Checkpoint Therapeutics Inc.
• F. Hoffmann-La Roche Ltd.
• Merck and Co. Inc.
• Pfizer Inc.

 

This statistical study of the PD-1 and PD-L1 inhibitors market encompasses successful business strategies deployed by the key vendors. The PD-1 and PD-L1 inhibitors market is fragmented and the vendors are entering into strategic alliances to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The PD-1 and PD-L1 market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for PD-1 and PD-L1 Inhibitors Market?

For more insights on the market share of various regions Request for a FREE sample now!

51% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for PD-1 and PD-L1 inhibitors in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Application Segments in the PD-1 and PD-L1 Inhibitors Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The PD-1 and PD-L1 inhibitors market share growth by the solid tumors segment will be significant during the forecast period.  The global PD-1 and PD-L1 inhibitors market has witnessed a significant increase in the approval of drugs for the treatment of various solid tumors in the last four years. This is primarily due to the high efficacy of PD-1 and PD-L1 inhibitors in blocking the cancer cells pathway and helping the T-cells to fight against the cancer-causing cells. The recent approval of IMFINZI, developed by AstraZeneca, for the treatment of urogenital cancer is expected to contribute heavily to the growth of the solid tumors segment.

This report provides an accurate prediction of the contribution of all the segments to the growth of the PD-1 and PD-L1 inhibitors market size and actionable market insights on post COVID-19 impact on each segment.

 

PD-1 and PD-L1 Inhibitors Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 19.11%
Market growth 2021-2025	$ 29.97 billion
Market structure	Fragmented
YoY growth (%)	18.40
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 51%
Key consumer countries	US, Germany, UK, Canada, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this PD-1 and PD-L1 Inhibitors Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive PD-1 and PD-L1 inhibitors market growth during the next five years
• Precise estimation of the PD-1 and PD-L1 inhibitors market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the PD-1 and PD-L1 inhibitors industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of PD-1 and PD-L1 inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch